CoinInsight360.com logo CoinInsight360.com logo
America's Social Casino

CoinDesk 2025-07-08 12:17:09

Semler Scientific Gets Buy Rating From Benchmark, $101 Price Target on Bitcoin Treasury Pivot

Benchmark's Mark Palmer initiated coverage of Semler Scientific (SMLR) with a buy rating and a $101 price target, citing the company’s dramatic pivot from medical diagnostics to bitcoin (BTC) accumulation as a key value driver. Semler, which spent over 15 years focused on chronic disease detection, adopted bitcoin as its primary treasury reserve asset in May last year. The move made it only the second U.S.-listed firm, after Michael Saylor's Strategy (MSTR), to adopt bitcoin as a treasury reserve asset. Since then, the company has acquired roughly 4,636 BTC for $430 million, with an average cost basis of $92,753 per bitcoin, the report said. Palmer noted that the stock rallied 178% in the six and a half months following its Bitcoin Standard announcement, peaking at $81.56 in December 2024. However, the analyst argued that Semler still trades at a steep discount compared to bitcoin treasury peers. Its multiple of net asset value (mNAV) sits at 1.25, compared to 4.29 for Japan-based Metaplanet (3350) and 6.45 for France’s Blockchain Group (ALTBG), the analyst noted. Benchmark believes this gap could close. Management recently appointed Joe Burnett as Director of Bitcoin Strategy and outlined bold BTC accumulation targets: 10,000 BTC by end of 2025, 42,000 by end of 2026, and 105,000 by end of 2027. The report notes that resolving legal and regulatory headwinds from Semler’s legacy healthcare business, including a Department of Justice (DOJ) investigation and Medicare reimbursement uncertainties, could help lift its valuation further. Benchmark’s $101 price target is based on a sum-of-the-parts valuation that assumes bitcoin will hit $225,000 by year-end 2026. Read more: Semler Scientific Trades at Premium to Bitcoin Holdings for First Time in Three Weeks

阅读免责声明 : 此处提供的所有内容我们的网站,超链接网站,相关应用程序,论坛,博客,社交媒体帐户和其他平台(“网站”)仅供您提供一般信息,从第三方采购。 我们不对与我们的内容有任何形式的保证,包括但不限于准确性和更新性。 我们提供的内容中没有任何内容构成财务建议,法律建议或任何其他形式的建议,以满足您对任何目的的特定依赖。 任何使用或依赖我们的内容完全由您自行承担风险和自由裁量权。 在依赖它们之前,您应该进行自己的研究,审查,分析和验证我们的内容。 交易是一项高风险的活动,可能导致重大损失,因此请在做出任何决定之前咨询您的财务顾问。 我们网站上的任何内容均不构成招揽或要约